The routine use of atypical antipsychotic agents: Maintenance treatment

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 19, 1998, Pages 18-22

  Kinon, Bruce J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; PATIENT EDUCATION; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CAREGIVERS; DYSKINESIA, DRUG-INDUCED; HUMANS; PIRENZEPINE; RISK ASSESSMENT; RISPERIDONE; SCHIZOPHRENIA;

EID: 0032425572     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Davis JM. Overview: maintenance therapy in psychiatry, I: schizophrenia. Am J Psychiatry 1975;132:1237-1245
2. Bartko G, Maylath E, Herczeg I. Comparative study of schizophrenic patients relapsed on and off medication. Psychiatry Res 1987;22(3):221-227
3. Hogarty GE, Ulrich RF, Mussare F, et al. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Dis Nerv Syst 1976;37(9):494-500
4. Johnson DA. The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatr Scand 1976;53:298-301
5. Dencker SJ, Lepp M, Malm U. Do schizophrenics well adapted in the community need neuroleptics? a depot neuroleptic withdrawal study. Acta Psychiatr Scand Suppl 1980;279:64-76
6. Cheung HK. Schizophrenics fully remitted on neuroleptics for 3-5 years-to stop or continue drugs? Br J Psychiatry 1981;138:490-494
7. Johnson DA. Long-term maintenance treatment in chronic schizophrenia: some observations on outcome and duration. Acta Psychiatr Belg 1981;81(2):161-172
8. Wistedt B. A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 1981;64:65-84
9. Kane JM. Outcomes: relapse and tardive dyskinesia. In: Syllabus and Proceedings Summary of the 150th Annual Meeting of the American Psychiatric Association; May 17-22, 1997; San Diego, Calif. No. 2C:263
10. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993;54:133-139
11. Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens. J Clin Psychiatry 1986;47(5, suppl):30-33
12. Marder SR, Van Putten T, Mintz J, et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987;44(6):518-521
13. Johnson DA, Ludlow JM, Street K, et al. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. Br J Psychiatry 1987; 151:634-638
14. Hogarty GE, McEvoy JP, Munetz M, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: results of a two-year controlled study. Arch Gen Psychiatry 1988;45:797-805
15. Kane JM, Davis JM, Schooler NR, et al. A one-year comparison of four dosages of haloperidol decanoate. Schizophr Res 1993;9:239-240
16. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Arch Gen Psychiatry 1997;54:453-463
17. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics, I: preliminary results for relapse rates. Arch Gen Psychiatry 1983;40:893-896
18. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138-1148. Correction 1991;148:819
19. Herz MI, Glazer WM, Mostert MA, et al. Intermittent versus maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry 1991;48:333-339
20. Jolley AG, Hirsch SR, Morrison E, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and so-cial outcome at two years. BMJ 1990;301(6756):837-842
21. Gaebel W, Frick U, Kopeke W, et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br J Psychiatry 1993;21:8-12
22. Brown GW, Birley JL, Wing JK. Influence of family life on the course of schizophrenic disorders: a replication. Br J Psychiatry 1972;121(562): 241-258
23. Vaughn C, Leff J. The measurement of expressed emotion in the families of psychiatric patients. Br J Soc Clin Psychol 1976;15(2):157-165
24. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41(8):892-897
25. Miller DD, Fleming F, Holman TL, et al. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994;55(10, suppl B):117-121
26. Kane J, Schooler N, Marder S. A six-month comparison of clozapine and haloperidol. Presented at the 35th annual meeting of the American College of Neuropsychopharmacology; December 8-13, 1996; San Juan, Puerto Rico
27. Breier A, Buchanan RW, Irish D, et al. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993;44(12): 1145-1149
28. Essock SM, Hargreaves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996;32(4):683-697
29. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15(5):917-926
30. Albright PS, Livingstone S, Keegan DL, et al. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clin Drug Invest 1996;11(5):289-299
31. Dellva MA, Tran P, Tollefson GD, et al. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997;48(12):1571-1577
32. Tran PV, Dellva MA, Tollefson GD, et al. Standard-dose oral olanzapine versus standard-dose oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998;172:499-505
33. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
34. Beasley C, Tollefson G, Dellva MA, et al. What is the differential risk of tardive dyskinesia with the atypical antipsychotic olanzapine? Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; December 8-12, 1997; Waikoloa, Hawaii